Leerink downgraded Karuna Therapeutics (KRTX) to Market Perform from Outperform with a price target of $330, up from $270, as the firm expects the stock to trade based on deal dynamics and no longer on fundamentals after Bristol Myers (BMY) agreed to acquire Karuna for $330 per share. The firm doesn’t believe it’s likely that another player will come in at a higher price and we doesn’t expect FTC pushback, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRTX:
- M & A News: Bristol-Myers (NYSE:BMY) to Acquire Karuna for $14B
- Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet
- Karuna Therapeutics initiated with bullish view at Citi, here’s why
- Karuna Therapeutics initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue